PHARMACY

Galen acquires DaunoXome from Gilead

BY Allison Cerra

SOUDERTON, Pa. — A Northern Ireland pharmaceutical company has acquired a chemotherapy agent from Gilead.

Galen said it has acquired DaunoXome (daunorubicin citrate liposome injection), an anthracycline chemotherapy agent that was first approved in the United States in 1996, and is indicated as a first-line cytotoxic therapy for advanced HIV-associated Kaposi’s sarcoma. Galen said its wholly owned subsidiary, Galen US, will market the drug in the United States. DaunoXome will be made available through wholesalers in the United States.

“We are delighted that we are now able to supply DaunoXome in the United States for the treatment of patients with this devastating disease,” Galen president Mark Scrutton said, “DaunoXome marks our first step into the oncology arena and this exciting, new acquisition provides us with the opportunity to offer more widely a much-needed therapy for patients with advanced HIV-associated KS.”


Interested in this topic? Sign up for our weekly Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Clinic operator Christie Clinic sells two pharmacies to Walgreens

BY Michael Johnsen

CHAMPAIGN, Ill. — Christie Clinic last week announced it had entered into a purchase agreement with Walgreens for the sale of two of the former’s pharmacy operations.

Walgreens will lease the space currently occupied by Christie Clinic for its new operations. The transfer is expected to be completed by the end of March. Walgreens plans to keep both pharmacy locations open and is renovating the facilities, including new signage.

Both pharmacies will be closed on March 31 and April 1 for minor renovations, as well as operational changes, and will open as Walgreens at 8:00 a.m. on April 2, the clinic operator said.

Christie Clinic operates 14 clinic locations throughout east central Illinois, as well as the Christie Clinic Cancer Center and C U Sleep, which houses the Department of Sleep Medicine.

 


Interested in this topic? Sign up for our weekly Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

FDA accepts NDA filing for Impax’s Parkinson’s disease treatment

BY Allison Cerra

HAYWARD, Calif. — The Food and Drug Administration has accepted a new drug application for the treatment of idiopathic Parkinson’s disease.

Impax Pharmaceuticals, the branded products division of Impax Labs, said it filed its NDA for the investigational drug IPX066, an extended-release capsule formulation of carbidopa-levodopa, for review in December 2011. IPX066 has been licensed to GlaxoSmithKline for countries outside the United States and Taiwan for development and marketing.

The Prescription Drug User Fee Date for a decision by the FDA is Oct. 21, Impax said.


Interested in this topic? Sign up for our weekly Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES